Navigation Links
Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
Date:8/20/2007

GRAND RAPIDS, Mich., Aug. 20 /PRNewswire/ -- The Center for Molecular Medicine (CMM) today said it was the only lab in the Midwest capable of testing nursing mothers for codeine risks cited in a Friday alert from the U.S. Food and Drug Administration (FDA).

Late Friday, the FDA issued an advisory noting new information about a very rare, but serious, side effect in nursing infants whose mothers are taking codeine and are also ultra-rapid metabolizers of that drug. The FDA advisory recommended physicians order a CYP2D6 genotyping test to determine how the patient will metabolize codeine in advance of its prescription.

The FDA noted that when codeine enters the body and is metabolized, it changes to morphine, which relieves pain. Many factors affect codeine metabolism, including a person's genetic make-up. Some people have a variation in a liver enzyme (CYP2D6) and may change codeine to morphine more rapidly and completely than other people. Results from the FDA-approved CYP2D6 test, available at the CMM, tell a physician how rapidly a specific patient will metabolize codeine based on a patient's genetic makeup.

"The CMM was created to offer physicians exactly this type of tool to prevent adverse drug reactions and better manage patient outcomes," said CMM Executive Director Daniel H. Farkas. "It is vital that any area physicians contemplating codeine for nursing mothers understand the critical need to complete a CYP2D6 test first in order to accurately determine how an individual's body will process that drug at different dosages."

The CMM performs the CYP2D6 test using the FDA-approved AmpliChip(R) system created by Roche Diagnostics. Using the test, physicians can have prior knowledge of how certain medications and levels of prescribed doses will affect their patient before beginning treatment.

Approximately 25 percent of all prescription drugs are metabolized by the enzymes measured by the AmpliChip(R) test. The test need only be done once in a person's lifetime to provide a permanent and critical reference capable of significantly improving care and reducing costs.

About the CMM

The Center for Molecular Medicine, a joint venture between Grand Rapids, Mich.-based Spectrum Health and Van Andel Institute (VAI), brings West Michigan a cutting-edge laboratory that will aid in early diagnoses and enhance personalized medicine. It offers 21st century molecular technologies for investigation of complex diseases like cancer, heart disease, mental illness and other conditions at the DNA, RNA and protein levels. The Center brings new and increased opportunities for diagnostics and pharmaceutical companies to conduct trials in a world-class medical and clinical research environment. For more information, visit http://www.cmmdx.org.


'/>"/>
SOURCE The Center for Molecular Medicine

Copyright©2007 PR Newswire.

Related biology technology :

1. NanoRite Innovation Center opens with small science, big promise
2. UW-Madison to receive $125M for bioenergy research center
3. Internet-enabled niche markets take center stage
4. TomoTherapy opens technical training center
5. Stem cell and regenerative medicine center to aid education and commerce
6. Mega-Metro Center may go beyond Chicago and Wisconsin
7. Berbee to expand at New Venture Center
8. Call centers and customer service: The good, the bad, and the clueless
9. Data centers: Buyers beware of over-hyped facilities
10. New angel capital centered on GenTel agreement with big pharma
11. Doyle proposes $2M for venture capital center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® test, ... clinically significant acute bacterial and viral respiratory tract infections by testing the ...
(Date:10/12/2017)... CA (PRWEB) , ... October ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed ... bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made ...
(Date:10/11/2017)... NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic ... one eye at a time. So which eye do you rinse first if a dangerous ... have Plum Duo Eye Wash with its unique dual eye piece. , “Whether ...
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
Breaking Biology Technology:
(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
(Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):